PET Scans Ontario
PET Registry

What is the PET Registry?

The Ontario PET Registry makes PET scans available to patients in certain cases where some evidence supports the benefit of PET scanning, but the evidence is too weak to support funding through the Ontario Health Insurance Program (OHIP).

The Registry collects additional data from participating patients to strengthen the evidence supporting the use of PET scans for eligible indications.

How do I enroll in the PET Registry?

Patients Physicians
Speak with your physician to determine if you are eligible for the PET Registry, and whether a PET scan is an appropriate diagnostic or treatment assessment tool for you.

Information on the reason for the PET scan, and the results, are used to strengthen the evidence supporting the use of PET scanning for the indication.
Review the list of Registry indications (below) to confirm that your patient is eligible for the Ontario PET Registry. If they are not, view these pages to find information about eligibility and access for the other uninsured programs:
Register now / Log in to the online referral tool to access PET-centre-specific forms and submit your completed request, including any relevant supporting documentation.

Want more information? Contact the PET Scans Ontario Information Line at 1-877-4PET-411 (1-877-473-8411; toll-free in Canada only).

Cancer indications

These indications are eligible for reimbursement through the Ontario PET Registry.

  • Anal canal cancer: for the initial staging of patients with T2-T4 squamous cell carcinoma of the anal canal with or without evidence of nodal involvement on conventional anatomical imaging.
  • Lymphoma staging: for the baseline staging of patients with Hodgkin's or non-Hodgkin's lymphoma
  • Melanoma: for the staging of melanoma patients with localized “high risk” tumours with potentially resectable disease; or for the evaluation of patients with melanoma and isolated metastasis at the time of recurrence when metastectomy is being contemplated.
  • Multiple myeloma/plasmacytoma:
    • Solitary plasmacytoma: for patients with presumed solitary plasmacytoma who are candidates for curative intent radiotherapy; OR
    • Smoldering myeloma: for workup of patients with smoldering myeloma and negative or equivocal skeletal survey; OR
    • Nonsecretory or oligosecretory myeloma: for baseline staging and/or response assessment.
  • Paediatric Registry (patients must be <18 years of age):
    • For the following cancer types (ICCC)
      • Bone/Cartilage - Osteosarcoma, Ewings sarcoma
      • Connective/Other soft tissue - Rhabdomyosarcoma, Other
      • Kidney - Renal Tumour
      • Liver - Hepatic Tumour
      • Lymphoma/PTLD – Hodgkin’s Lymphoma, Non-Hodgkin’s Lymphoma
      • Primary Brain - Astrocytoma, Medulloblastoma, Ependymoma, Other
      • Reproductive - Germ Cell Tumour
      • Sympathetic Nervous System - Neuroblastoma MIBG negative
      • Other – LCH, Melanoma of the Skin, Thyroid
    • For the following indications
      • Initial Staging
      • Monitoring response during treatment/determine response-based therapy
      • Rule out progression prior to further therapy
      • Suspected recurrence/relapse
      • Rule out persistent disease
      • Select optimal biopsy site

Neurological Indications

  • Epilepsy: for patients with medically-intractable epilepsy being assessed for epilepsy surgery

This list will be updated as Registries are closed, or new Registries are added. Please check back periodically.